Evidence map›Paper›PMID 35684392›Full record

ArticleMolecules (Basel, Switzerland)2022

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Shabnam Shaabani, Louis Gadina, Ewa Surmiak, Zefeng Wang, Bidong Zhang, Roberto Butera, Tryfon Zarganes-Tzitzikas, Ismael Rodriguez, Justyna Kocik-Krol, Katarzyna Magiera-Mularz and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Shabnam ShaabaniDepartment of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0001-5546-7140
Louis GadinaFaculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland.
Ewa SurmiakFaculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland.ORCID 0000-0002-4103-4675
Zefeng WangDepartment of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands.
Bidong ZhangDepartment of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands.
Roberto ButeraDepartment of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands.
Tryfon Zarganes-TzitzikasDepartment of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands.
Ismael RodriguezFaculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland.ORCID 0000-0001-9722-610X
Justyna Kocik-KrolFaculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland.ORCID 0000-0002-3779-3118
Katarzyna Magiera-MularzFaculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland.ORCID 0000-0002-4826-6380
Lukasz SkalniakFaculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland.ORCID 0000-0002-6707-6697
Alexander DömlingDepartment of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands.ORCID 0000-0002-9923-8873
Tad A HolakFaculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland.ORCID 0000-0001-9369-6024
Jagiellonian University · PLUniversity of Groningen · NL

Funding

Real-time discovery of inhibitors among billion compounds for preview and downloadR01GM097082 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAMACHO, CARLOS J. · 2011 to 2020
$2.5M
Accelerated Early stage drug dIScovery No 675555COFUNDs ALERT No 665250European Lead Factory No 115489KWF Kankerbestrijding No 10504National Science Center 2017/26/A/ST5/00572NIGMS NIH HHS R01 GM097082NIH HHS 2R01GM097082-05Prominent No 754425Qatar National Research Foundation NPRP6-065-3-012
6 · The paper itself

Abstract

New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex. Most of the compounds displayed excellent inhibitory activity against PD-1/PD-L1, as assessed by the homogenous time-resolved fluorescence (HTRF) binding assay. Among them, compound

Indexed as

B7-H1 AntigenProgrammed Cell Death 1 ReceptorThalidomideBiphenyl CompoundsHumansLigandsB7-H1 AntigenbiphenylBiphenyl CompoundsLigandspomalidomideProgrammed Cell Death 1 ReceptorThalidomideimmune checkpoint blockadePD-1/PD-L1small-molecule inhibitors

Identifiers

PMID35684392
PMCPMC9181982
OpenAlexW4281747243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.